Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DanDrit Biotech was a biopharmaceutical company focused on developing dendritic cell-based immunotherapies for cancer. Its lead candidate MelCancerVac targeted the MAGE-A antigen family using autologous dendritic cells loaded with allogeneic tumor lysate. The company expanded its pipeline through acquisitions—including OncoSynergy’s anti-CD29 mAb OS2966 for glioblastoma/ovarian cancer and later Enochian’s HIV/AIDS gene therapy assets. After acquiring Enochian in February 2018, the combined entity rebranded as Enochian BioSciences and shifted focus to advanced gene/cell therapies for oncology and infectious diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DanDrit Biotech USA, Inc..